Bending Spoons IPO Priced at $29, Opens at $31
Several companies made their market debuts last week, with Bending Spoons, ITG and Neutron Holdings opening for trading across a mix of pricing levels.LATEST IPOS AND DIRECT LISTINGS:Bending Spoonsopened on July 1 at $31.00. The company priced its 57.97M share initial public offering at $29.00, above the $26.00-$28.00 range. Bending Spoons is a digital applications company whose portfolio includes note-taking app Evernote, video platform Vimeo, events marketplace Eventbrite and AOL.ITG, Inc.opened on July 1 at $18. The company priced 19.51M shares at $16.00, below the $19.00-$22.00 range. ITG is a provider of end-to-end services to the communications and digital infrastructure industries.Neutron Holdingsopened on July 1 at $27. The firm priced 6.96M shares at $25.00, in the middle of the deal range of $24.00-$26.00. Neutron Holdings, doing business as Lime, describes itself as "a leading global shared micromobility business" that partners with cities to deploy e-bikes and e-scooters to serve shorter distance trips.RECENT SPAC IPOS:Viking Acquisition Corp. IIopened on July 2 at $10.04. The blank check company's efforts to identify a prospective target business will not be limited to a particular industry or geographic region.Osprey Acquisition IIIopened on July 1 at $10.03. The blank check company may pursue an acquisition opportunity in any business or industry or at any stage of its corporate evolution, but says its primary focus will be to "identify companies that are deploying disruptive technologies and next-generation infrastructure that modernize energy systems, enable AI-driven optimization, and support the resilient, sustainable backbone of global connectivity."PERFORMANCE:Prices as of 10:30 am ET on Monday, July 6 -Bending Spoons – down over 6% at $33.76;ITG, Inc. – down about 6% at $14.60;Neutron Holdings – fractionally down at $24.88.RECENT IPOS TO WATCH:SpaceX, Forbright, ERock, and WhiteHawk Mineralsare already seeing coverage roll out, while Avalanche Treasury Co.is among stocks that could see new coverage this week as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include Jersey Mike's Subs, Kardigan, Inspire Brands, and Tarsier Pharma.Clickto see upcoming IPO calendar on TipRanks.Jersey Mike's Subshas filed an initial public offering of shares of Class A common stock. The company has applied to list its shares of Class A common stock on the New York Stock Exchange under the trading symbol "JMKE." Morgan Stanley, Jefferies, and J.P. Morgan are acting as global coordinators and joint bookrunning managers for the offering. Barclays and Guggenheim Securities are acting as co-global coordinators and joint bookrunning managers. BofA Securities, Goldman Sachs, Evercore ISI, UBS Investment Bank, Baird, Wells Fargo Securities, William Blair, RBC Capital Markets, Deutsche Bank Securities, Wolfe Nomura Alliance, Piper Sandler, Raymond James, Stifel, TD Securities, BTIG, Mizuho, Societe Generale, and Truist Securities are acting as joint bookrunning managers. Blackstone Capital Markets, Loop Capital Markets, and Tigress Financial Partners are acting as co-managers.Kardiganhas filed an initial public offering of shares of its common stock. The company has applied to list its common stock on the Nasdaq Global Market under the symbol "KARD." JP Morgan, Jefferies, Leerink Partners, and TD Cowen are acting as the underwriters for the offering.Inspire Brandsannounced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. Inspire Brands expects to use the net proceeds of the proposed offering to repay outstanding indebtedness under its existing term loan facility and pay offering fees and expenses.Tarsier Pharma Ltd.filed for an initial public offering of its ordinary shares and applied to list its ordinary shares on the NYSE American under the symbol "TARX". The prospectus stated: "Tarsier Pharma is developing TRS01 and TRS02, novel product candidates based on dazdotuftide, a new molecule with a new mechanism of action for uveitis and uveitic glaucoma. We are attempting to address a significant, underserved market opportunity and have engaged closely with the FDA on our clinical development strategy, including a Special Protocol Assessment agreement for our planned pivotal trial... Although we are still early in this journey, I believe we have the technology, the team, the discipline, and the persistence required to build an enduring company."Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.
